The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid
Table 2
Fatty acid content of plasma phospholipids in healthy volunteers (HV) and inflammatory bowel disease (IBD) patients.
Fatty acid (% of total)
Baseline
2 weeks
4 weeks
8 weeks
Change in fatty acid content from baseline to week 8*
%CV
HV
n-6 PUFAs
C18:2 LA
19.1 ± 2.2**
17.3 ± 1.3
16.4 ± 1.3
15.9 ± 1.1
−3.2 (−4.6 to −1.9)***
75.2
C20:4 AA
13.6 ± 0.9
11.6 ± 1.7
10.5 ± 0.9
10.3 ± 0.8
−3.2 (−3.7 to −2.8)
25.0
n-3 PUFAs
C20:5 EPA
0.3 ± 0.2
4 ± 0.8
4.5 ± 1
4.6 ± 0.6
4.3 (4.0–4.7)
14.5
C22:5 DPA
0.3 ± 0.3
2.6 ± 0.7
2.7 ± 0.5
2.8 ± 0.5
2.5 (2.2 to 2.8)
19.8
C22:6 DHA
2.7 ± 0.8
4.6 ± 0.7
4.0 ± 0.5
4.2 ± 0.7
1.5 (0.9–2.1)
70.9
IBD
n-6 PUFAs
C18:2 LA
18.5 ± 1.6
16 ± 1.1
15.7 ± 1
15.2 ± 1
−3.4 (−4.1 to −2.6)
45.2
C20:4 AA
14.2 ± 1
10.7 ± 0.9
11 ± 0.8
10.6 ± 0.9
−3.6 (−4.1 to −3.1)
32.0
n-3 PUFAs
C20:5 EPA
0.6 ± 0.2°
4.2 ± 0.7
4.8 ± 0.6
4.7 ± 0.5
4.1 (3.8 to 4.3)
12.3
C22:5 DPA
0.5 ± 0.2°
2.6 ± 0.5
2.9 ± 0.4
3.1 ± 0.6
2.6 (2.3 to 2.9)
24.0
C22:6 DHA
3.3 ± 0.6°
4.5 ± 0.5
4.4 ± 0.5
4.9 ± 0.4
1.6 (1.4 to 1.8)
32.1
Values are mean ± SD. for the difference in individual n-3 PUFA content between IBD patients and HV. *Absolute change in % fatty acid content. ***Data are the mean and 95% confidence interval. All < 0.01. PUFAs: polyunsaturated fatty acids. LA: linoleic acid. AA: arachidonic acid. EPA: eicosapentaenoic acid. DPA: docosapentaenoic acid. DHA: docosahexaenoic acid. CV: coefficient of variation.
